Our study adds to the accumulating evidence suggesting that NAF-1 can improve the chemotherapeutic sensitivity of pancreatic cancer cells and improve the clinical effectiveness of drugs. The gene discussed is NAF1; the disease is familial pancreatic carcinoma.